<DOC>
	<DOCNO>NCT00025597</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Giving chemotherapy drug surgery may shrink tumor remove surgery . PURPOSE : Phase II trial study effectiveness combination chemotherapy follow surgery treating infant newly diagnose neuroblastoma .</brief_summary>
	<brief_title>Combination Chemotherapy Followed Surgery Treating Infants With Newly Diagnosed Neuroblastoma .</brief_title>
	<detailed_description>OBJECTIVES : - Determine survival morbidity infant newly diagnose stage II III unresectable neuroblastoma without MYCN amplification treat vincristine cyclophosphamide , etoposide carboplatin , cyclophosphamide , doxorubicin , vincristine follow surgery . - Determine whether deletion chromosome 1p diploidy/tetraploidy prognostic factor patient . - Determine whether prognostic criterion could use future therapeutic stratification patient . OUTLINE : This multicenter study . Patients stratify accord symptomatic spinal cord involvement ( yes v ) . Patients without evidence symptomatic spinal cord compression receive vincristine IV day 1 cyclophosphamide IV day 1-5 . Treatment repeat every 14 day 2 course . Patients eligible surgery undergo surgical resection remove study . Patients ineligible surgery 2 course initial chemotherapy , least 25 % response initial chemotherapy , receive 2 additional course vincristine cyclophosphamide . Patients eligible surgery undergo surgical resection remove study . Patients ineligible surgery 2 additional course initial chemotherapy disease progression receive etoposide IV 2 hour carboplatin IV 1 hour day 1-3 . Treatment repeat every 21 day 2 course . Patients eligible surgery undergo surgical resection remove study . Patients remain ineligible surgery disease progression etoposide carboplatin receive cyclophosphamide IV 1 hour day 1-5 , doxorubicin IV 6 hour day 4 5 , vincristine IV day 1 5 . Treatment repeat every 21 day 2 course . Patients undergo surgical resection biopsy . Patients symptomatic spinal cord compression receive initial treatment etoposide carboplatin . Patients improve symptom resectable disease initial chemotherapy undergo surgical resection biopsy . Patients remain ineligible surgery improvement symptom initial chemotherapy receive cyclophosphamide , doxorubicin , vincristine . Patients undergo surgical resection biopsy . Patients follow within 6 month annually 5 year . PROJECTED ACCRUAL : A total 100 patient accrue study within 4 year .</detailed_description>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm newly diagnose stage II III neuroblastoma ganglioneuroblastoma Unresectable disease No MYCN amplification ( i.e. , few 10 copy ) No metastasis bone marrow No radiological bone lesion skeleton PATIENT CHARACTERISTICS : Age : Under 12 month diagnosis Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : No evidence liver disease ultrasound Renal : Not specify PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Not specify Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>1 Year</maximum_age>
	<verification_date>November 2001</verification_date>
	<keyword>localize unresectable neuroblastoma</keyword>
</DOC>